Literature DB >> 35283435

Contribution of phosphate and FGF23 to CKD progression.

Kyle P Jansson1,2, Alan S L Yu1,2, Jason R Stubbs1,2.   

Abstract

PURPOSE OF REVIEW: Progressive forms of chronic kidney disease (CKD) exhibit kidney inflammation and fibrosis that drive continued nephron loss; however, factors responsible for the development of these common pathologic features remain poorly defined. Recent investigations suggest pathways involved in maintaining urinary phosphate excretion in CKD may be contributing to kidney function decline. This review provides an update on recent evidence linking altered phosphate homeostasis to CKD progression. RECENT
FINDINGS: High dietary phosphate intake and increased serum concentrations of fibroblast growth factor 23 (FGF23) both increase urinary phosphate excretion and are associated with increased risk of kidney function decline. Recent investigations have discovered high concentrations of tubular phosphate promote phosphate-based nanocrystal formation that drives tubular injury, cyst formation, and fibrosis.
SUMMARY: Studies presented in this review highlight important scientific discoveries that have molded our current understanding of the contribution of altered phosphate homeostasis to CKD progression. The collective observations from these investigations implicate phosphaturia, and the resulting formation of phosphate-based crystals in tubular fluid, as unique risk factors for kidney function decline. Developing a better understanding of the relationship between tubular phosphate handling and kidney pathology could result in innovative strategies for improving kidney outcomes in patients with CKD.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35283435      PMCID: PMC9232955          DOI: 10.1097/MNH.0000000000000793

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   3.416


  45 in total

1.  Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Authors:  Lourdes Craver; Maria Paz Marco; Isabel Martínez; Montserrat Rue; Merce Borràs; Maria Luisa Martín; Felipe Sarró; José Manuel Valdivielso; Elvira Fernández
Journal:  Nephrol Dial Transplant       Date:  2007-01-05       Impact factor: 5.992

2.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

3.  Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1).

Authors:  Kevin J Filipski; Matthew F Sammons; Samit K Bhattacharya; Jane Panteleev; Janice A Brown; Paula M Loria; Markus Boehm; Aaron C Smith; Andre Shavnya; Edward L Conn; Kun Song; Yan Weng; Carie Facemire; Harald Jüppner; Valerie Clerin
Journal:  ACS Med Chem Lett       Date:  2018-04-12       Impact factor: 4.345

4.  Serum fibroblast growth factor-23 is associated with incident kidney disease.

Authors:  Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

5.  Protection of renal function and of nutritional status in uremic rats by means of a low-protein, low-phosphorus supplemented diet.

Authors:  G Barsotti; L Moriconi; A Cupisti; L Dani; F Ciardella; S Lupetti; S Giovannetti
Journal:  Nephron       Date:  1988       Impact factor: 2.847

Review 6.  Chronic Kidney Disease.

Authors:  Angela C Webster; Evi V Nagler; Rachael L Morton; Philip Masson
Journal:  Lancet       Date:  2016-11-23       Impact factor: 79.321

7.  A micropuncture study of renal phosphate transport in rats with chronic renal failure and secondary hyperparathyroidism.

Authors:  N Bank; W S Su; H S Aynedjian
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

8.  Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus.

Authors:  K Zeller; E Whittaker; L Sullivan; P Raskin; H R Jacobson
Journal:  N Engl J Med       Date:  1991-01-10       Impact factor: 91.245

9.  Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

Authors:  Marinella Ruospo; Suetonia C Palmer; Patrizia Natale; Jonathan C Craig; Mariacristina Vecchio; Grahame J Elder; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-08-22

10.  Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Mireille El Ters; Pengcheng Lu; Jonathan D Mahnken; Jason R Stubbs; Shiqin Zhang; Darren P Wallace; Jared J Grantham; Arlene B Chapman; Vicente E Torres; Peter C Harris; Kyongtae Ty Bae; Douglas P Landsittel; Frederic F Rahbari-Oskoui; Michal Mrug; William M Bennett; Alan S L Yu
Journal:  Kidney Int Rep       Date:  2021-01-16
View more
  1 in total

1.  Osteopontin Regulates Phosphate Solubility to Prevent Mineral Aggregates in CKD.

Authors:  John D Imig
Journal:  Kidney360       Date:  2022-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.